Enanta insiders sold over 9,000 shares Dec. 5 as stock rose slightly despite quarterly loss and revenue miss.

On December 5, 2025, multiple Enanta Pharmaceuticals insiders, including CEO Jay Luly, Scott Rottinghaus, Brendan Luu, and Yat Sun Or, sold a combined total of over 9,000 shares at $14.23 per share, reducing their stakes. The stock rose $0.51 to close at $14.60, with below-average volume. Enanta reported a quarterly loss of $0.87 per share, beating estimates by $0.26, but revenue of $15.13 million fell short of forecasts. The company, focused on small molecule drugs for viral infections and liver diseases, has a market cap of $421.36 million and a consensus "Moderate Buy" rating with a $20.33 target.